In September 2022, in tandem with the Global Summit of National Ethics Committees [LINK] in Lisbon, Portugal, the Health Ethics & Governance Unit hosted a workshop to explore experiences of research ethics review during COVID-19 with representatives from over 20 countries. The objectives of the meeting were: - to identify what worked and did not work in terms of research ethics review during COVID-19; - to discuss clinical trial designs such as adaptive trials and their impact on research ethics review during COVID-19; - to draft recommendations for various stakeholders and a report on the workshop findings; and - to contribute to a possible revision of WHO’s guidance for research ethics committees for rapid review of research during public health emergencies. It was agreed that additional guidance about ethical review in emergencies was not required, other than for specific issues such as new trial methods. Rather, research ethics committees need to be better prepared, better resourced, and better connected. Attention should be paid to improving relations between research ethics committees and other parts of the research ecosystem; clarifying roles and responsibilities and improving coordination at all levels; retaining and building on flexible systems and approaches developed during the pandemic; and ensuring that research ethics committees have the necessary resources to contribute effectively to the shared aim of ethical,effective research. For more detail see the meeting report [LINK] and an article in BMC Medical Ethics, co-authored by all the speakers at the meeting.